Antidepressant News and Research

RSS

Antidepressants are medicines that treat depression. Your doctor can prescribe them for you. They can improve your mood, sleep, appetite and concentration. It may take several weeks for them to help. There are several types of antidepressants. You and your doctor may have to try several before finding what works best for you.

Esketamine nasal spray superior in achieving remission in patients with treatment-resistant depression

Both severe depression and treatment-resistant depression are common. Up to one third of patients do not respond to conventional therapy with antidepressants such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs).

5 Oct 2023

Esketamine outperforms one of the standard drugs for treatment-resistant major depression

A major clinical trial shows that the drug, esketamine, one of the two main forms of ketamine, outperforms one of the standard treatments for treatment-resistant major depression.

4 Oct 2023

Internet-delivered CBT may help reduce depressive symptoms in patients with multiple sclerosis

Major depressive disorder affects up to 50% of all individuals with multiple sclerosis (MS) at some point during their lifetime and can lead to lower quality of life, greater disease progression and higher mortality.

27 Sep 2023

One health wake-up call: London's river data highlights environmental perils

The largest-ever spatiotemporal monitoring of chemicals/contaminants of emerging concern (CECs) in London waterways.

26 Sep 2023

Kombucha tea shows promise in lowering blood sugar levels for type 2 diabetics

A recent clinical trial conducted at Georgetown University Hospital suggests that kombucha tea may hold potential as an anti-hyperglycemic agent, reducing fasting blood glucose levels in adult patients with type 2 diabetes. While the results are promising, further research with larger sample sizes is needed to solidify the health benefits of kombucha in managing diabetes.

25 Sep 2023

Long-term consumption of ultra-processed foods may increase depression risk

The effects of ultra-processed food (UPF) on mental health.

25 Sep 2023

Can deep brain stimulation unlock the cure for severe depression?

A multidisciplinary team of clinicians, engineers, and neuroscientists has identified a unique biomarker in the brain that indicates recovery from treatment-resistant depression, utilizing deep brain stimulation (DBS) and artificial intelligence. The discovery, which allows for real-time monitoring and tailoring of treatment, could revolutionize the approach to managing severe forms of depression.

21 Sep 2023

New brain biomarker predicts recovery from treatment-resistant depression

Using a novel deep brain stimulation (DBS) device capable of recording brain signals, researchers have identified a pattern of brain activity or "biomarker" related to clinical signs of recovery from treatment-resistant depression.

20 Sep 2023

Transforming postpartum depression treatment with neurosteroids

A new study in Neuropsychopharmacology delves into the mechanisms of action of brexanolone, the first FDA-approved, rapid-acting antidepressant specifically for postpartum depression (PPD). The research highlights brexanolone's potential anti-inflammatory effects and its impact on GABAA receptors, offering insights into its efficacy and suggesting avenues for further study.

19 Sep 2023

Antidepressants may reduce negative memories, improve memory in depressed individuals

New research from Rice University finds that antidepressants may actually reduce negative memories in individuals suffering from depression while improving overall memory function.

11 Sep 2023

Study finds way to help teen night owls adjust to their natural sleep cycles

Promoting healthy sleep in teen night owls brings adolescents' biology and school demands in alignment.

8 Sep 2023

What are the efficacy and safety of psilocybin in patients with major depressive disorder?

The safety, timing, magnitude, and durability of the antidepressant psilocybin on patients with major depressive disorders.

4 Sep 2023

Adolescence stress exposure impacts rodent brain development and behavior

Adolescence stress exposure in rodents can lead to reduced hippocampal cell proliferation, neuroplasticity, and cognitive impairments, as well as increased depressive-like behaviors. These effects may persist into adulthood but with variable impact.

27 Aug 2023

Genetic reasons behind Raynaud's phenomenon discovered

Researchers at Queen Mary University of London's Precision Healthcare Research Institute (PHURI) and the Berlin Institute of Health (BIH) at Charité – Universitätsmedizin Berlin have identified the genetic causes of Raynaud's phenomenon.

4 Aug 2023

GABA-modulating treatments could help tackle cognitive, affective symptoms associated with depression

Depression is a complex condition correlated with multiple differences in brain function and mechanisms. A new paper spanning known data about the neurotransmitter GABA and its principal receptors showcases evidence of the receptors' importance in depression and potential as therapeutic targets.

3 Aug 2023

Uncommon genetic allele variants may play a vital role in treatment-resistant depression, finds study

The association between treatment-resistant depression and uncommon functional genetic alleles.

3 Aug 2023

Antidepressants may help prevent bipolar depression relapse

Treatment with modern antidepressants may help prevent patients with bipolar disorder from relapsing into a depressive episode, according to an international clinical trial led by researchers at the University of British Columbia.

2 Aug 2023

New drug shows promise for treating chronic neuropathic pain

A non-opioid designer molecule for treating chronic neuropathic pain by calming hyperactive pain-sensing neurons in the peripheral nervous system has had promising results in a preclinical study conducted by researchers at Weill Cornell Medicine and the Burke Neurological Institute.

2 Aug 2023

Study highlights metabolite targets for depression prevention that are easily modifiable through diet interventions

Researchers used a UHPLC and mass spectrometry-based Metabolon platform to identify and characterize circulating metabolites associated with depression.

1 Aug 2023

Trial evaluates purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder

Researchers investigated the safety and pharmacokinetics of JNJ-54175446 in a double-blind, multicenter, randomized controlled trial (RCT).

31 Jul 2023